BeOne Medicines AG
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- John V. Oyler
- Full Time Employees
- 12,000
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 94 Aeschengraben 27 Basel PA Switzerland 4051
- IPO Date
- Feb 3, 2016
- CIK
- 0001651308
- Website
- beonemedicines.com
- Similar Companies
- Business
- BeOne Medicines Ltd. (ONC) is a global oncology company that discovers, develops and commercializes innovative cancer treatments spanning hematology and solid tumors; its marketed products include BRUKINSA (zanubrutinib), a second-generation BTK inhibitor approved for chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström's macroglobulinemia; TEVIMBRA (tislelizumab), a PD-1 inhibitor approved for Hodgkin lymphoma, esophageal squamous cell carcinoma, gastric/gastroesophageal junction adenocarcinoma and small cell lung cancer; and others such as pamiparib and denosumab; the company advances a diverse pipeline of novel therapeutics including sonrotoclax (BCL2 inhibitor), BGB-16673 (BTK degrader), BGB-43395 (CDK4 inhibitor), BG-68501 (CDK2 inhibitor), xaluritamig (STEAP1 x CD3 bispecific), TARLATAMAB-DLLE (CD3 x DLL3 bispecific), antibody-drug conjugates like BG-C9074, bispecific T-cell engagers and PROTACs through internal R&D and collaborations. BeOne Medicines operates in over 45 countries across six continents with major presence in the United States, China, Europe, Australia and Asia; it was founded in 2010 by John V. Oyler and Xiaodong Wang, and is headquartered in Basel, Switzerland following redomiciliation in May 2025 from Cambridge, Massachusetts. Recent developments include a November 2024 rebranding from BeiGene Ltd. with stock ticker change to ONC in January 2025; an August 2025 royalty purchase agreement with Royalty Pharma for up to $950 million on IMDELLTRA (tarlatamab-dlle) sales excluding China, providing $885 million upfront; positive Phase 3 results in August 2025 for sonrotoclax in relapsed/refractory chronic lymphocytic leukemia; European Commission approval in August 2025 for TEVIMBRA as neoadjuvant/adjuvant treatment for non-small cell lung cancer; 41% total revenue growth to $1.4 billion in Q3 2025 driven by 51% increase in global BRUKINSA sales; and pipeline advancements showcased at ASH 2025 including long-term BRUKINSA data and new combinations in B-cell malignancies.
BeOne Medicines to Announce Second Quarter 2026 Financial Results on August 5
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma
BeOne Medicines' Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
BeOne Medicines AG (ONC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
BeOne Medicines Ltd. - Sponsored ADR (ONC) Upgraded to Strong Buy: What Does It Mean for the Stock?
BeOne Medicines AG (ONC) Discusses Solid Tumor Portfolio Progress and R&D Pipeline Strategy at ASCO Transcript
BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3
Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's
BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 2026
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 2026
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts
BeOne Medicines Launches One Save Changes Everything, a Global Cancer Care Awareness Campaign with Soccer Legend Tim Howard
BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer
BeOne Medicines' BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma
BeOne Medicines AG (ONC) Q1 2026 Earnings Call Transcript
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
Here Are Monday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Airbnb, Alphabet, Check Point Software, GlobalFoundries, Internatioinal Paper, Trade Desk, and More
U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA